Skip to main content
Premium Trial:

Request an Annual Quote

Teva to Commercialize Noninvasive Prenatal Test from Illumina's Verinata Health

NEW YORK (GenomeWeb News) – Illumina said today that its noninvasive prenatal testing subsidiary Verinata Health has signed an exclusive agreement with Teva Pharmaceutical Industries to commercialize its Verifi test in Israel.

Under the terms of the five-year agreement, Teva will be the exclusive distributor of Verifi in Israel. All tests will be run in Verinata's CLIA-certified laboratory in California, while Israel's Clalit Health Services will provide reimbursement for Verifi through supplemental insurance.

The MOR Institute of Medical Data, through its relationship with Teva, will make the test available to customers of Clalit Health Services who are at a high risk of having a fetus with a chromosomal abnormality. Additionally, Clalit Health Services will establish a 9,000-patient clinical outcomes registry to collect performance data that it will share with Verinata.

Beginning today, MOR will provide a nursing service that allows women to have their sample collected from their homes as well as from MOR clinics.

"With the test now available in several international markets, we look forward to expanding our commercial presence by continuing to partner with leading organizations around the globe," Verinata's VP of global commercial operations, Vance Vanier, said in a statement.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.